1. FDA has approved expanded label for fluocinolone acetonide intravitreal implant (ILUVIEN).
2. The implant is now indicated for chronic noninfectious uveitis affecting the posterior segment (NIU-PS) of the eye, as well as its previous approval for diabetic macular edema (DME). 
3. The expanded label is expected to enhance supply security and access for appropriate patients with NIU-PS and DME.
4. Potential ocular adverse reactions include cataracts, visual acuity reduction, macular edema, and uveitis. 

Source: ANI Pharmaceuticals